Ethyl 4-amino-5-(4-chloro-3-nitrobenzoyl)-2-((2-(trifluoromethyl)phenyl)amino)thiophene-3-carboxylate, 95%, 25mg

Glycine, min. 99%, for synthesis, 2.5 kg, plastic packaging.

Thalidomide-O-amido-C4-NH2 (TFA), 100mg

Ethyl 4-(3-bromo-5-methylphenyl)-4-oxobutyrate, 97.0%, 1g

2-(2-Chloroethoxy)acetic acid, 95.0%, 5g

2-(2-Bromo-4,5-diethoxyphenyl)acetonitrile, 97%, 100mg

6-(Tritylthio)hexanoic acid, 99.0%, 250mg

(4-(2-Nitro-4-(trifluoromethyl)phenoxy)phenyl)boronic acid, 95.0%, 250mg

cyclohexyl 3-(4-methylpiperazinomethyl)phenyl ketone, 97.0%, 1g

4-Methoxybenzyl (1S,2S)-2-((R)-4-((9H-xanthen-9-yl)methyl)-1-(4-methoxybenzyl)-2,5-dioxoimidazolidin-4-yl)cyclopropane-1-carboxylate, 98%, 250mg

Tris(2,2'-bipyridine)nickel(II) bromide, 95%, 5g

1-(2,2-Diethoxyethyl)pyrazole-4-boronic acid, 98%, 1g

tert-Butyl 2-(6-bromo-5-methyl-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl)-2-methylpropanoate, 98%, 100mg